Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2–advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial

Javier Salvador Bofill a,*, Fernando Moreno Anton b, Cesar Augusto Rodriguez Sanchez c, Elena Galve Calvo d, Cristina Hernando Melia e, Eva Maria Ciruelos Gil f, Maria Vidal g, Begona Jimenez-Rodriguez h, Luis De la Cruz Merino i, Noelia Martinez Janez j, Rafael Villanueva Vazquez k, Ruben de Toro Salas l, Antonio Anton Torres m, Isabel Manuela Alvarez Lopez n, Joaquin Gavila Gregori o, Vanesa Quiroga Garcia p, Elena Vicente Rubio q, Juan De la Haba-Rodriguez r, Santiago Gonzalez-Santiago s, Nieves Diaz Fernandez t, Agusti Barnadas Molins u, Blanca Cantos Sanchez de Ibarguen v, Juan Ignacio Delgado Mingorance w, Meritxell Bellet Ezquerra x, Sonia de Casa y, Asuncion Gimeno z, Miguel Martin z

a Hospital Universitario Virgen del Rocio, Instituto de Biomedicina de Sevilla (IBIS), Sevilla, Spain
b Hospital Clinico San Carlos, Madrid, Spain
c Hospital de la Santa Creu i Sant Pau and CIBERONC Breast Cancer Programme, Department of Medicine, Hospital Universitari Vall d’Hebron and Institut d’Investigació Biomèdica de Barcelona (VHIO), Barcelona, Spain
d Hospital Universitario de Salamanca-IBSAL, Salamanca, Spain
e Hospital Universitario de Basurto, Bilbao, Spain
f Hospital Universitario 12 de Octubre, Madrid, Spain
g Departamento de Medicina, Hospital Universitario de Salamanca, Salamanca, Spain
h Hospital Universitario Virgen de la Macarena, Sevilla, Spain
i Hospital Universitario San Juan de Alicante, Alicante, Spain
j Hospital Universitario San Pedro de Alcántara, Madrid, Spain
k Hospital Universitario Ciudad de Jaén, Jaén, Spain
l Hospital Universitario del Príncipe de Asturias, UGCI Oncología Médica, Hospital Reina Sofia, Valencia, Spain
m Hospital Universitario de Santiago de Compostela, CEDEN, Spain
n Hospital Universitario de Alcorcón, Alcorcón, Madrid, Spain
o Hospital Universitario de Granada, Granada, Spain
p Hospital Universitario Gregorio Maranon, Madrid, Spain
q Hospital Universitario Infanta Cristina, Badajoz, Spain
r Hospital Universitario Vall d’Hebron, Barcelona and Instituto Oncologia Vall d’Hebron (VHIO), Barcelona, Spain
s Hospital Universitario de Salamanca-IBSAL, Salamanca, Spain
t Hospital Universitario San Juan de Alicante, Alicante, Spain
u Hospital Universitario de La Princesa, Madrid, Spain
v Hospital Universitario de Navarra, Pamplona, Spain
w Hospital Universitario Virgen del Rocio, Av. Manuel Siurot, s/n, 41013 Sevilla, Spain
x Hospital Universitari Sant Pau, Barcelona, Spain
y Hospital Universitario 12 de Octubre, Madrid, Spain
z Hospital Universitario Virgen del Rocio, Av. Manuel Siurot, s/n, 41013 Sevilla, Spain

* Corresponding author. Unidad de Oncología, Hospital Universitario Virgen del Rocio, Av. Manuel Siurot, s/n, 41013 Sevilla, Spain.
E-mail address: francescoj.salvador.sspa@juntadeandalucia.es (J. Salvador Bofill).

https://doi.org/10.1016/j.breast.2022.09.006
Received 21 July 2022; Received in revised form 20 September 2022; Accepted 24 September 2022
Available online 28 September 2022
0960-9776/© 2022 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
1. Introduction

Breast cancer is the most common malignancy in Spanish women, with approximately 33,000 new cases estimated to be diagnosed in 2021; it is also the second leading cause of cancer-related mortality for Spanish women [1]. Invasive breast cancer cases represent just under 30% of all invasive cancers diagnosed in Spanish women [2,3]. Breast cancer rates in Spain have remained stable over the past decades with an incidence of ~88 per 100,000, which is lower than the European average (108.8 per 100,000) [2]. Approximately 19% of women diagnosed with breast cancer in Spain were aged under 45 years [4]. Although tumor biology in younger, premenopausal women tends to be more aggressive than in older ones, these women are often underrepresented in clinical trials [5,6].

Hormone receptor-positive (HR+) breast cancer is the most common subtype, representing up to 75% of breast cancer cases [7,8]. Endocrine therapy (ET) is a long-established first-line treatment for HR+ advanced breast cancer (ABC); however, the effectiveness of ET is limited by the development of endocrine resistance, which prevents patients from achieving long-term clinical benefit [9]. The combination of ET with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors has resulted in prolonged clinical benefit in patients with HR+, human epidermal growth factor receptor 2-negative (HER2−) ABC, and is now the recommended first-line treatment for these patients as per the ESO-ESMO and NCCN guidelines [10,11].

Ribociclib, an orally bioavailable, highly selective CDK4/6 inhibitor, is currently approved by Spanish Health Authorities in combination with an aromatase inhibitor or fulvestrant as first-line treatment for pre-/postmenopausal patients with HR+, HER2− ABC [12]. The phase 3 MONALEESA-2, -3 and -7 trials have established the efficacy and safety of ribociclib in combination with ET in patients with HR+, HER2− ABC [13-17], showing superiority vs. ET alone in prolonging progression-free survival (PFS) and overall survival (OS), regardless of ET partner, line of therapy, or menopausal status.

Despite these positive results, evidence for the safety and efficacy of ribociclib plus ET in a broader patient population is lacking, as patients with poor performance status, central nervous system (CNS) metastases and those who have received chemotherapy for ABC are frequently excluded from clinical trials. The phase 3b CompLEEment-1 trial assessed the safety and tolerability of ribociclib plus letrozole in a larger and broader population of patients with HR+, HER2− ABC than those eligible for previous phase 3 trials [18]. Unlike MONALEESA-2 and MONALEESA-7, the CompLEEment-1 trial population included patients who were male, had CNS metastases, and/or an Eastern Cooperative Oncology Group (ECOG) performance status of 2. Furthermore, CompLEEment-1 also included patients who had received prior chemotherapy for advanced disease, who are frequently excluded from clinical trials despite clinical data showing that a significant number of patients with HR+, HER2− ABC receive chemotherapy as first-line treatment [19]. Safety and efficacy data for ribociclib in CompLEEment-1 were consistent with those of MONALEESA-2 and -7; the median time to progression was 27.1 months (95% confidence interval [CI], 25.7 to not reached) [18].

Here, we present a detailed analysis of the efficacy and safety of ribociclib plus letrozole in a broad population of Spanish patients with HR+, HER2− ABC, including populations of interest (NCT02941926).

Trial registration: ClinicalTrials.gov NCT02941926

2. Methods

2.1. Study design and treatment

CompLEEment-1 (NCT02941926) is an open-label, single arm, multicenter phase 3b study assessing the overall safety, tolerability, and clinical efficacy of ribociclib in combination with letrozole in men, and pre- and postmenopausal women with HR+, HER2− ABC who did not receive prior ET for advanced disease [18]. The study consists of 2 phases (Supplementary Fig. 1): a core phase running from the First Patient First Visit (FPFV) until 18 months after the Last Patient First Visit (LPFV), and an extension phase running from 18 months after LPFV (end of the core phase) to the Last Patient Last Visit (LPLV). Patients transitioned to the extension phase only if they were still obtaining clinical benefit from the treatment at the end of the core phase and had no access to ribociclib outside of the clinical trial.

Patients received ribociclib at a total daily starting dose of 600 mg (3 tablets of 200 mg) on a 3 weeks on/1 week off schedule, with or without food. Additionally, patients received 2.5 mg letrozole orally once a day on a continuous schedule through a 28-day cycle. Male patients and premenopausal female patients also received 3.6 mg goserelin (as an injectable subcutaneous implant) or 7.5 mg leuprolide (as an intramuscular injection) once per cycle. Treatment continued until disease progression, unacceptable toxicity, death, or discontinuation from study treatment for any reason. All patients were followed for 30 days following the last ribociclib dose. Dose reduction, dose interruption, and/or discontinuation of ribociclib were permitted for the management...
of severe adverse events (AEs), whereas dose reductions were not permitted for letrozole, goserelin or leuprolide [18]. Data cutoff was 8 November 2019.

2.2. Key inclusion and exclusion criteria

Eligible patients included adult males, pre- and postmenopausal females aged ≥18 years with locoregionally recurrent or metastatic HR+ HER2- ABC not amenable to curative therapy. Only those patients who had received ≤1 line of chemotherapy and no prior ET for advanced disease were enrolled in this study. Patients with a treatment-free interval (TFI) > 12 months from completion of (neo)adjuvant therapy with letrozole or anastrozole and those who had received treatment in the metastatic setting with letrozole or anastrozole for ≤28 days prior to enrollment were eligible. All enrolled patients displayed adequate bone marrow and organ function and had an ECOG performance status of ≤2. At screening, eligible patients had corrected QT interval (QTc) < 450 ms as measured by Fridericia’s correction (QT interval corrected for heart rate using Fridericia’s formula, QTcF), and a resting heart rate of ≥50 beats per minute.

Key exclusion criteria included receipt of any prior CDK4/6 inhibitor or systemic hormonal therapy for ABC or concurrent use of other anticancer therapy; known history of HIV infection; clinically significant, uncontrolled heart disease and/or cardiac repolarization abnormalities; and concurrent malignancy or malignancy within 3 years prior to starting study drug (except receptively treated basal cell or squamous cell carcinoma, non-melanoma skin cancer; or curatively resected cervical cancer). Patients with CNS metastases were also excluded, unless the patient had completed any prior therapy for CNS disease 4 weeks before the start of study treatment and CNS lesions were clinically stable.

2.3. Endpoints and study assessments

The primary objective of this study was to assess the safety and tolerability of ribociclib in combination with letrozole in a broad patient population. Primary endpoints included the number of patients experiencing any adverse events (AEs); grade 3/4 AEs; serious AEs (SAEs); adverse events of special interest (AESIs); AEs leading to dose reduction, interruption, or discontinuation; and AE-related deaths. AESIs were defined according to ongoing reviews of ribociclib safety data, and included neutropenia, QTcF prolongation, and hepatobiliary toxicity (measured as elevation of aspartate aminotransferase [AST] and alanine aminotransferase [ALT] blood levels). Safety assessments involved monitoring and recording all AEs, grade 3/4 AEs and SAEs, AESIs, AEs leading to drug discontinuation and deaths. MedDRA version 22.1 and CTCAE version 4.03 were used to define AESIs and AEs (preferred term), respectively.

Secondary endpoints related to the clinical efficacy of ribociclib plus letrozole included time-to-progression (TTP) based on investigators’ assessment (defined as time from date of treatment initiation to the date of event); overall response rate (ORR) for patients with measurable disease (defined as the proportion of patients with a best overall response of complete response [CR] or partial response [PR]); and clinical benefit rate (CBR), defined as the proportion of patients with a best overall response of CR or PR, or an overall lesion response of stable disease (SD), lasting for at least 24 weeks, as per local review. Tumor response, which was assessed locally, was based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria. Tumor assessments were performed according to the current standard of care; assessments were recommended to take place every 12 weeks until disease progression.

Another secondary endpoint was health-related quality of life (HRQoL) using the Functional Assessment of Cancer Therapy–Breast Cancer (FACT-B) questionnaire [20], translated into Spanish. This was only completed by female patients due to the nature of the questionnaire. Responses to the FACT-B questionnaire were collected using electronic devices at Day 1 of each cycle up to Cycle 6, every 2 cycles up to Cycle 12 and every 3 cycles thereafter.

2.4. Statistical analysis

Demographic and other baseline data including disease characteristics were summarized descriptively for the Full Analysis Set (FAS) of the Spanish patients’ subgroup. The FAS included all patients who received at least one dose of study treatment (either ribociclib or letrozole or goserelin/leuprolide [if applicable] in the core phase).

The safety analysis was conducted using the Safety Set (SS) of the Spanish patients’ subgroup, which included all patients in the FAS. The primary safety variables (AEs, SAEs, AESIs, AEs leading to dose reduction or interruption, and AEs leading to discontinuation and deaths) were summarized by count and percentage.

The clinical efficacy analysis was conducted using the FAS. ORR and CBR were calculated and summarized using frequency tables with associated 2-sided exact 95% CI, whereas TTP was estimated using the Kaplan-Meier method. The patient-reported outcome (PRO) analysis set consisted of all female patients in the FAS population for whom baseline and at least one postbaseline measurements were available.

2.5. Ethics

The study was designed, implemented, and reported in accordance with the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable local regulations, and with the ethical principles laid down in the Declaration of Helsinki. The protocol and informed consent form were reviewed and approved by a properly constituted Institutional Review Board/Independent Ethics Committee/Research Ethics Board before study commencement. Written informed consent was obtained from all patients. A steering committee oversaw the conduct of the trial as per the approved protocol. Representatives of the trial sponsor, Novartis Pharmaceuticals (East Hanover, NJ), collected and analyzed the data.

3. Results

3.1. Patient demographics and baseline characteristics

Patient disposition and baseline characteristics of all patients enrolled in the global study have been described previously [18]. Overall, 526 Spanish patients were enrolled and received at least one dose of study treatment between April 2017 and November 2019. The median follow-up time was 26.97 months (range, 21.4–33.84). The median duration of exposure to ribociclib was 18.6 months, while this was 18.8 months for letrozole (n = 526) and 16.8 months for goserelin (n = 173); no Spanish patients received leuprolide. The median average daily dose of ribociclib was 600.0 mg (240.0–600.0), while the median dose intensity was 576.7 mg/day (204.5–682.4). Overall, 58.0% of patients discontinued study treatment (Supplementary Table 1); the most common reasons for treatment discontinuation were progressive disease (33.8%) and AEs (15.0%).

Baseline patient characteristics showed a diverse population in terms of age and disease characteristics (Tables 1 and 2). The median age was 54 years (range, 24–85), and 15.8% of patients were aged >70 years (Table 1). The vast majority of patients were female (99.2%, with 4 male patients [0.8%] enrolled), and 64.4% were postmenopausal women; most patients (97.7%) had an ECOG performance status of ≤1.

At baseline, 56.5% of patients had visceral metastases, whereas 1.5% of patients had CNS metastases (Table 2). Overall, 37.3% of patients had ≥3 metastatic sites at baseline, whereas 8.7% of patients had received prior chemotherapy for advanced disease.
Disease characteristics.

Table 2

| Characteristic                                      | All Patients | Spanish Patients |
|-----------------------------------------------------|--------------|------------------|
| Median time since initial diagnosis, months (range)  | 42.5 (0.1–469.9) | 46.8 (0.1–412.8) |
| Disease-free interval, n (%)                         | 1041 (32.1)  | 158 (30.0)       |
| De novo                                              | 2201 (67.8)  | 368 (70.0)       |
| Non-de novo                                          | 382 (11.8)   | 62 (11.8)        |
| ≤24 months                                           | 1819 (56.0)  | 306 (58.2)       |
| Hormone receptor status, n (%)                       | 3231 (99.5)  | 525 (99.8)       |
| Progesterone receptor-positive                       | 2608 (80.3)  | 417 (79.3)       |
| Site of metastases, n (%)                            |              |                  |
| Bone                                                 | 2409 (74.2)  | 401 (76.2)       |
| Bone-only                                            | 704 (21.7)   | 151 (28.7)       |
| Breast                                               | 183 (5.6)    | 29 (5.5)         |
| CNS                                                  | 51 (1.6)     | 8 (1.5)          |
| Visceral                                             | 1992 (61.4)  | 297 (56.5)       |
| Liver                                                | 862 (26.6)   | 143 (27.2)       |
| Lung                                                 | 1416 (43.6)  | 296 (37.3)       |
| Other                                                | 295 (9.1)    | 36 (6.8)         |
| Skin                                                 | 110 (3.4)    | 8 (1.5)          |
| Lymph nodes                                          | 1250 (38.5)  | 180 (34.2)       |
| Other                                                | 163 (5.0)    | 15 (2.9)         |
| Metastatic sites, n (%)                              |              |                  |
| 0                                                    | 15 (0.5)     | 2 (0.4)          |
| 1                                                    | 903 (27.8)   | 175 (33.3)       |
| 2                                                    | 923 (28.4)   | 153 (29.1)       |
| 3                                                    | 644 (19.8)   | 99 (18.8)        |
| 4                                                    | 375 (11.6)   | 55 (10.5)        |
| ≥5                                                   | 386 (11.9)   | 42 (8.0)         |
| Prior (neo)adjuvant ET, n (%)                        | 1156 (35.6)  | 207 (39.4)       |
| Anti-estrogen                                        |              |                  |
| Aromatase inhibitors                                 | 1091 (33.6)  | 117 (22.2)       |
| Prior chemotherapy for advanced disease, n (%)       | 194 (6.0)    | 46 (8.7)         |

A patient with multiple severity grades for an AE is only counted under the maximum grade. AE, adverse event; SAE, serious adverse event.

Table 3

| Category                                      | All Grades n (%) | Spanish Patients, N = 526 |
|-----------------------------------------------|------------------|---------------------------|
| AEs                                           |                  |                            |
| Treatment-related                             | 521 (99.0)       | 401 (76.2)                |
| SAEs                                          | 112 (21.3)       | 93 (17.7)                 |
| Treatment-related                             | 19 (3.6)         | 16 (3.0)                  |
| Fatal SAEs                                    | 10 (1.9)         | 10 (1.9)                  |
| Treatment-related                             | 2 (0.4)          | 2 (0.4)                   |
| AEs leading to discontinuation                | 83 (15.8)        | 47 (8.9)                  |
| Treatment-related                             | 63 (12.0)        | 36 (6.8)                  |
| AEs leading to dose adjustment/interruption   | 390 (74.1)       | 350 (66.5)                |
| Treatment-related                             | 351 (66.7)       | 324 (61.6)                |

A patient with multiple severity grades for an AE is only counted under the maximum grade. AE, adverse event; SAE, serious adverse event.

3.2. Safety

Nearly all patients experienced an AE (99.0%), with Grade ≥3 AEs occurring in 76.2% of patients (Table 3) and all-grade SAEs occurring in 21.3% (Grade ≥3 SAEs, 17.7%). Only 15.8% of all-grade AEs (Grade ≥3, 8.9%) led to treatment discontinuation, while 74.1% (Grade ≥3, 66.5%) required dose adjustment or interruption.

The majority of AEs were assessed as treatment-related (all grade, 93.9%; Grade ≥3, 66.9%), but the rates of SAEs assessed as related to treatment were low (all grade, 3.6%; Grade ≥3, 3.0%). Two deaths were assessed as resulting from treatment-related AEs: the causes were pneumonitis, and pancytopenia and sepsis (it should be noted that the latter patient was concomitantly receiving metomizole).

Most common AEs reported were neutropenia (all grade, 77.4%; Grade ≥3, 59.5%), anemia (all grade, 37.8%; Grade ≥3, 1.9%), abdomen (all grade, 28.1%; Grade ≥3, 0.6%), arthralgia (all grade, 24.0%; Grade ≥3, 0.3%), and anemia (all grade, 20.3%; Grade ≥3, 1.9%) (Table 4). Rates of all-grade neutropenia were similar across patient subgroups of interest (patients aged >70 years, patients who received prior chemotherapy for advanced disease, and patients with visceral metastases at diagnosis), although increased proportions of patients aged >70 years experienced Grade ≥3 neutropenia (64.0% vs. 59.5% in all patients) (Table 4). The reported frequency of anemia was also increased in patients aged >70 years compared with all patients (all grade, 37.3% vs. 20.3%; Grade ≥3, 5.3% vs. 1.9%). Increased proportions of these elderly patients also experienced constipation (22.7% vs. 16.9%), alopecia (26.7% vs. 16.7%), vomiting (22.7% vs. 15.4%), and decreased appetite (25.3% vs. 11.0%) compared with the whole patient population; the majority of these events were grade 1 or 2. Meanwhile, patients who had received prior chemotherapy for advanced disease reported increased rates of all-grade arthralgia (32.6% vs. 24.0% in all patients).

Most cases of neutropenia were managed with dose interruption or dose reduction, while nearly half of hypertransaminasemia cases were managed with dose reduction; on the other hand, few cases of QTcF prolongation required this approach (Table 5). The numbers of patients who required permanent drug withdrawal due to neutropenia, ALT increase, AST increase and QTcF prolongation were 4 (0.8%), 29 (5.5%), 5 (10.5%) and 4 (0.8%), respectively. The rates of recovery/resolution were greater than the rates of non-recovery/non-resolution for all AESIs except transaminase increase. AESIs very rarely led to hospitalization (0–0.2% of patients) and no fatal AESIs were recorded.

At data cutoff, 10 patients (1.9%) had died, most of them as a result of disease progression (n = 5, 1.0%). Other causes of death were embolism, hepatic failure, pneumonitis, respiratory failure and sepsis (one patient each); of these, the deaths due to pneumonitis and pancytopenia and sepsis (it should be noted that the latter patient was concomitantly receiving metomizole).

Nearly all patients experienced an AE (99.0%), with Grade ≥3 AEs occurring in 76.2% of patients (Table 3) and all-grade SAEs occurring in 21.3% (Grade ≥3 SAEs, 17.7%). Only 15.8% of all-grade AEs (Grade ≥3, 8.9%) led to treatment discontinuation, while 74.1% (Grade ≥3, 66.5%) required dose adjustment or interruption.
ORR rates compared with patients with no visceral metastases at baseline (Supplementary Table 2). Metastatic status also affected efficacy; patients with ≥3 metastatic sites more likely to experience a CR (5.2% vs. 1.4% for patients with ≥3 metastatic sites at baseline). Finally, patients with no visceral metastases at baseline (Supplementary Table 2). Overall, 8.7% of Spanish patients had received prior chemotherapy for advanced disease had substantially higher ORR and CBR rates compared with those exposed to chemotherapy at baseline (48.5% and 69.5% vs. 31.3% and 59.4%, respectively), largely driven by higher rates of PR (45.1% vs. 28.1% in patients with prior chemotherapy treatment).

In terms of PROs, HRQoL remained stable throughout the study without any major changes (Supplementary Fig. 2); median (SD) FACT-B scores were recorded as 101.2 (16.4%) at baseline and 93.3 (19.6%) at end of treatment, with a median change from baseline of −7.3.

4. Discussion

Our results support the clinical safety, tolerability and efficacy of treatment with ribociclib in combination with letrozole in a broad population of Spanish patients with HR+, HER2− ABC who had not previously received ET for their advanced disease. Overall, the data are consistent with those reported in the global CompLEEment-1 study [18] and support the use of ribociclib plus letrozole in the first-line setting for patients with HR+, HER2− ABC. Moreover, these results demonstrate the reproducibility and robustness of treatment with ribociclib and letrozole in this patient population across different environments and local settings.

The Spanish patient population enrolled in CompLEEment-1 represented 14% of the global population of the study and reflected a broad group of patients with HR+, HER2− ABC that was more representative of a real-world patient population than subjects included in other randomized phase 3 trials of CDK4/6 inhibitors in combination with aromatase inhibitors; in particular, a substantial proportion of patients in this trial had received chemotherapy for advanced disease [13,15,21]. Interim safety results from the Spanish population subset in CompLEEment-1 reported using an earlier cut-off date were consistent with previous data from MONALEESA-2, MONALEESA-7, and the CompLEEment-1 global cohort, and confirmed the predictable and manageable safety profile of ribociclib in combination with letrozole as first-line treatment for patients with HR+, HER2− ABC [22]. Spanish CompLEEment-1 patients had a lower median age compared with those enrolled in the global study (54.0 vs 58.0 years, respectively); the proportion of patients aged <65 years was also larger among the Spanish subset (76.0% vs 66.9% in the global study). Consistent with this observation, a lower proportion of Spanish patients were postmenopausal (64.4% vs 76.6% in the global study). Similar proportions of patients had ECOG ≤1 (97.7% vs 96.3% in the global study), while more Spanish patients had <3 metastatic sites at baseline (62.7% vs 56.7% in the global study). Overall, 8.7% of Spanish patients had received chemotherapy for advanced disease, compared with 6.0% in the global study; this slightly higher percentage could reflect a more aggressive treatment approach for Spanish women, which could be explained by

Table 4
Adverse events reported in >15% of patients in subgroups of interest.

| Preferred Term | All patients N = 526 | Age >70 years N = 75 | Prior chemotherapy N = 46 | Visceral metastases N = 297 |
|----------------|----------------------|----------------------|---------------------------|---------------------------|
| Number of patients with >1 event | 521 (99.0) | 401 (76.2) | 75 (100.0) | 63 (84.0) |
| | 45 (97.6) | 31 (67.4) | 293 (98.7) | 224 (75.4) |
| Neutropenia | 407 (77.4) | 313 (59.5) | 58 (77.3) | 48 (64.0) |
| | 35 (76.1) | 24 (52.2) | 226 (76.1) | 169 (56.9) |
| Asthenia | 199 (37.7) | 10 (1.9) | 31 (41.3) | 4 (5.3) |
| | 10 (21.7) | 0 | 109 (26.7) | 7 (2.4) |
| Nausea | 148 (28.1) | 3 (0.6) | 21 (28.0) | 0 |
| | 12 (26.1) | 0 | 89 (30.0) | 0 (0.7) |
| Arthralgia | 126 (24.0) | 0 | 12 (16.0) | 0 |
| | 15 (32.6) | 0 | 67 (22.6) | 0 |
| Anemia | 107 (20.3) | 10 (1.9) | 28 (37.3) | 4 (5.3) |
| | 9 (19.6) | 1 (2.2) | 63 (21.2) | 8 (2.7) |
| Constipation | 89 (16.9) | 1 (0.2) | 17 (22.7) | 1 (1.3) |
| | 4 (8.7) | 0 | 47 (15.8) | 1 (0.3) |
| Alopecia | 88 (16.7) | 0 | 20 (26.7) | 0 |
| | 1 (2.2) | 0 | 48 (16.2) | 0 |
| Diarrhea | 83 (15.8) | 4 (0.8) | 12 (16.0) | 0 |
| | 9 (19.6) | 1 (2.2) | 45 (15.2) | 2 (0.7) |
| Vomiting | 81 (15.4) | 4 (0.8) | 17 (22.7) | 1 (1.3) |
| | 6 (13.0) | 0 | 46 (15.5) | 2 (0.7) |
| Decreased appetite | 58 (11.0) | 1 (0.2) | 19 (25.3) | 1 (1.3) |
| | 1 (2.2) | 0 | 36 (12.1) | 1 (0.3) |

A patient with multiple severity grades for an adverse event is only counted under the maximum grade.

Table 5
Adverse events of special interest.

| Preferred Term | All patients N = 526 |
|----------------|----------------------|
| N (%)<sup>a</sup> | Neutropenia | Liver Enzyme Elevation | QTcF Prolongation<sup>b</sup> |
|----------------|------------------|------------------------|--------------------------|
| ALT AST        | 409 (77.8) | 78 (1.48) | 60 (1.14) |
| Leading to dose interruption                   | 299 (56.8) | 34 (6.5) | 25 (4.8) |
| Leading to dose reduction                       | 90 (17.1)  | 6 (1.1)  | 3 (0.6)  |
| Leading to dose withdrawal                      | 4 (0.8)    | 29 (5.5) | 25 (4.8) |
| Leading to hospitalization                      | 15 (2.9)   | 2 (0.4)  | 4 (0.8)  |
| Medication or therapy taken                     | 242 (46.0) | 44 (8.4) | 35 (6.7) |
| Not recovered/not resolved                      | 223 (42.4) | 37 (7.0) | 34 (6.5) |
| Recovered/resolved                              | 376 (71.5) | 46 (8.7) | 33 (6.3) |
| With sequelae                                   | 9 (1.7)    | 0        | 1 (0.2)  |
| Leading to death                                | 0          | 0        | 0        |

<sup>a</sup> Percentage value calculated based on 526 patients. A patient is counted no more than once in each AE outcome. If a patient has AEs with different outcomes, the patient will be counted in several outcomes. If the patient has several events with the same outcome, he/she will be counted only once in the corresponding outcome line.

<sup>b</sup> Includes “Electrocardiogram QT prolonged”, “Electrocardiogram QT interval abnormal”, “Syncope” and “Long QT syndrome”.

46.6% (95% CI: 40.9, 52.5) and 68.5% (95% CI: 62.8, 73.7), respectively (Supplementary Table 2). Overall, 3.4% of patients experienced a CR and 43.3% a PR. ORR and CBR were higher for patients aged <50 years than for those aged ≥50 years. Patients aged <50 years also had increased CR rates (5.1% vs. 2.5% for age ≥50 years). In terms of menopausal status, ORR and CBR were similar for pre- and postmenopausal women, although CR rates were higher for premenopausal women (Supplementary Table 2). Metastatic status also affected efficacy rates, with patients presenting with visceral metastases having higher ORR rates compared with patients with no visceral metastases at baseline (47.7% vs 43.6%, respectively; Supplementary Table 3); the number of metastatic sites also affected efficacy rates, with patients with <3 metastatic sites more likely to experience a CR (5.2% vs. 1.4% for patients with ≥3 metastatic sites at baseline). Finally, patients with no metastatic sites had ORR rates compared with patients with no visceral metastases at baseline (Supplementary Table 2).
of 25.4 months [18]; this was comparable to the median PFS population in the global CompLEEment-1 study, with a median follow-up of 26.4 months) and MONALEESA-7 (23.8 months [95% CI: 19.2, not reached], with a median follow-up of 19.2 months). The similarity of median PFS measures across studies is of note as the CompLEEment-1 study enrolled a much broader patient population, including patients who had received chemotherapy for advanced disease [13,15]; these results highlight the efficacy of ribociclib in a patient population more representative of real-world patients.

ORR and CBR for Spanish patients with measurable disease at baseline were similar to those reported in the global study (46.6% and 68.5% vs 43.6% and 69.1%, respectively). The ORR was lower than those reported in the MONALEESA-2 and MONALEESA-7 trials for patients with measurable disease at baseline (54.5% and 51.0%, respectively) [13,15]. This may be due to the differences in patient population enrolled in CompLEEment-1, although it should also be noted that response assessment in this study was not centralized, but rather depended on the local standard of care. Age <50 years, presence of visceral metastases at baseline, <3 metastatic sites and no prior chemotherapy treatment for advanced disease all correlated with higher ORR and CBR in Spanish patients, while rates were similar for pre- and postmenopausal women. It should be noted that patients with visceral metastases are more likely to have measurable disease and thus be evaluable for response, which could explain the higher ORR and CBR rates in patients with visceral metastases at baseline. FACT-B scores were maintained relative to baseline, reflecting preservation of HRQoL.

A potential limitation of CompLEEment-1 is that tumor assessments were performed according to the current standard of care in different locations; response assessment timings may have varied, with different intervals according to the local standard of care. However, we believe this is an actual strength of the study, showing the robustness of response to ribociclib and supporting the utility of this type of analysis in a local population. Efficacy and PRO data should be interpreted with some caution given the lack of randomization and a control arm.

Overall, these findings support the efficacy and manageable safety profile of ribociclib in combination with letrozole as first-line treatment in a population of Spanish patients with HR+/HER2– ABC approaching that of a real-world setting.

**Funding**

This study was funded by Novartis Pharmaceuticals. The sponsor was involved in the study design, the collection, analysis, and interpretation of data, and the writing of the manuscript.
Conflict of interest/disclosures

JSB has received research grants from AstraZeneca, Lilly, Pfizer and Roche; consulting fees from AstraZeneca, Daiichi Sankyo, Gilead, Lilly, Pfizer, Roche and Seagen; honoraria from Lilly, Novartis and Pfizer. FMA has received research grants from Pfizer; consulting fees from AstraZeneca, Daiichi Sankyo, Eisai, MSD, Pfizer, Roche and Seagen; honoraria from Pfizer; travel grants from Daiichi Sankyo, Novartis and Pfizer. EGC has received research grants from Pfizer; consulting fees from AstraZeneca, Daiichi Sankyo, Gilead, Pfizer, Pharmamar, Roche and Seagen; honoraria from Eisai, Novartis and Pfizer; travel grants from Novartis, Pfizer and Roche. CHM has received honoraria from Novartis; travel grants from Novartis, Pfizer and Roche. EMCG has received honoraria from AstraZeneca, Daiichi Sankyo, Lilly, Novartis, Pfizer, Roche and Seagen; travel grants from AstraZeneca, Daiichi Sankyo, Novartis and Pfizer; has participated in advisory boards for AstraZeneca, Daiichi Sankyo, Lilly, Novartis, Pfizer, Roche and Seagen. MV has received honoraria from Daiichi Sankyo, Novartis, Pfizer and Roche; travel grants from Pfizer and Roche; has participated in advisory boards for Novartis and Roche. LDLCM has received honoraria from AstraZeneca, BMS, Incyte, MSD and Roche; travel grants from Roche. RVV has received consulting fees from Novartis; honoraria from Eisai, Lilly and Novartis; payment for expert testimony from Novartis; travel grants from Lilly, Novartis and Roche; has participated in advisory boards for Novartis. AAT has taken advisory/consultancy roles for Eli Lilly and Gilead; has received honoraria from AstraZeneca-Daichii-Sanykio, Eli Lilly, Pfizer and Seagen. JGG has received honoraria from AstraZeneca, Daiichi Sankyo, Lilly, Novartis, Pfizer, Roche and Seagen; has participated in advisory boards for AstraZeneca, Daiichi Sankyo, Lilly, Novartis, Pfizer, Roche and Seagen. VQG has been an invited speaker for Novartis and is a steering committee member for Roche. EVR has received honoraria from Lilly, Novartis, Pfizer and Roche; travel grants from Lilly, Novartis, Pfizer and Roche. JDLHR has received consulting fees from Lilly, Novartis, Pfizer, Roche and Seagen; honoraria from Lilly, Novartis, Pfizer, Roche and Seagen; payment for expert testimony from Lilly, Novartis, Pfizer, Roche and Seagen; travel grants from Lilly, Novartis, Pfizer, Roche and Seagen; has patents planned, issued or pending with Roche; has participated in advisory boards for Lilly, Novartis, Pfizer, Roche and Seagen. SGS has received honoraria from AstraZeneca, Clovis, GSK, Novartis and Pfizer; travel grants from GSK, Pfizer and Roche; has participated in advisory boards for AstraZeneca, GSK, Lilly and Seagen. ABM has received institutional grants from Bristol Myers Squibb, Lilly, MSD, Novartis, Pfizer and Roche; consulting fees from AstraZeneca, Exact Sciences, Gilead, Lilly, Pfizer, Roche and Seagen; honoraria from AstraZeneca, Novartis, Pfizer and Roche; travel grants from Pfizer and Roche; has participated in advisory boards for Exact Sciences, Gilead, Lilly, MSD, Pfizer, Roche, Seagen. BCSDi has received honoraria from Eisai, GSK and Novartis; travel grants from Novartis, Pfizer and Teva; has participated in advisory boards for Pfizer. MBE has received honoraria from Lilly, Novartis and Pfizer; travel grants from Pfizer; has participated in advisory boards for Lilly, Novartis and Pfizer. SDC and AG are Novartis employees. MM has received research grants from Novartis, PUMA and Roche; honoraria from Lilly, Novartis, Pierre Fabre, Pfizer and Roche; has a consulting or advisory role with AstraZeneca, Lilly, Novartis, Pharmamar, Pfizer, Revisors and Taiho Pharmaceutical; has participated in speaker’s bureaus for Lilly/ImClone, Pierre Fabre and Roche. CARSS, BJR, NDF, NMJ, RDT3, and JIDM have no conflicts of interest to disclose.

Ethics statement

The study was designed, implemented, and reported in accordance with the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable local regulations, and with the ethical principles laid down in the Declaration of Helsinki. The protocol and informed consent form were reviewed and approved by a properly constituted Institutional Review Board/Independent Ethics Committee/Research Ethics Board before study commencement. Written informed consent was obtained from all patients. A steering committee oversaw the conduct of the trial as per the approved protocol. Representatives of the trial sponsor, Novartis Pharmaceuticals (East Hanover, NJ), collected and analyzed the data.

Data sharing statement

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.

Acknowledgements

The authors would like to thank Vanesa Martinez Lopez, PhD, of Novartis Ireland Ltd, for medical writing support, which was funded by Novartis Farma S.A. in accordance with Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3).

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.breast.2022.09.006.

References

[1] SEOM. Las cifras del cancer en Espana. 2021.
[2] Galceran J, Amecia J, Carulla M, Mateo S, Quirin JR, Rojas D, et al. Cancer Incidence in Spain. 2015. Clin Transl Oncol 2017;19(7):799–825.
[3] Lopez-Muniz JJ Chacin, de la Cruz Merino L, Gavila Gregorio J, Martinez Duenas E, Oliveira M, Segul Palmer MA, et al. SEOM clinical guidelines in advanced and recurrent breast cancer (2018). Clin Transl Oncol 2019;21(12):31–45.
[4] GEICAM. Proyecto El Alamo III. Available from: http://www.geicam.org/wp-con tent/uploads/2017/04/Lib_ElAlamoIII_Anexo1.pdf 2014.
[5] Ademuyiwa FO, Cyrl A, Ivanovich J, Thomas MA. Managing breast cancer in younger women: challenges and solutions. Breast Cancer (Dove Med Press) 2016;8:1–12.
[6] Menen RS, Hunt KK. Considerations for the treatment of young patients with breast cancer. Breast J 2016;22(6):667–72.
[7] Miller TW, Ballo JM, Fox EM, Ghazoui Z, Dunbier A, Anderson H, et al. ESR-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. Cancer Discov 2011;1(4):338–51.
[8] Thangavel C, Dean JL, Ertel A, Knudsen KE, Aldaz CM, Wilkiewicz AK, et al. Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. Endocr Relat Cancer 2011;18(3):333–45.
[9] García-Becerra R, Santos N, Díaz L, Camacho J. Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance. Int J Mol Sci 2012;14(1):108–45.
[10] Cardoso F, Paluch-Shimon S, Senukus E, Curigliano G, Aapro MS, Andre F, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol 2020;31(12):1623–49.
[11] NCCN. Breast cancer treatment guidelines. 2022. Version 2.
[12] Camberley UKN. KissqIR summary of product characteristics. 2017.
[13] Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol 2018;29(7):1541–7.
[14] Slamon DJ, Neven P, Chia P, Fasching PA, De Laurentiis M, Im SA, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer. MONALEESA-3. J Clin Oncol 2018;36(24):2465–72.
[15] Tripathy D, De la Cruz Merino L, Gavila Gregorio J, Martínez Duenas E, Oliveira M, Segul Palmer MA, et al. SEOM clinical guidelines in advanced and recurrent breast cancer (2018). Clin Transl Oncol 2019;21(12):31–45.
Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med 2020;382(6):514–24.

Im SA, Lu YS, Bardia A, Harbeck N, Colleoni M, Franke F, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med 2019;381(4):307–16.

De Laurentiis M, Borstnar S, Campone M, Warner E, Bofill JS, Jacot W, et al. Full population results from the core phase of ComPLEximent-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population. Breast Cancer Res Treat 2021;189(3):689–99.

Brufsky AM. Delaying chemotherapy in the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. Clin Med Insights Oncol 2015;9:137–47.

Brady MJ, Cella DF, Mo F, Bonomi AE, Tulsky DS, Lloyd SR, et al. Reliability and validity of the functional assessment of cancer therapy-breast quality-of-life instrument. J Clin Oncol 1997;15(3):974–86.

Goetz MP, Toi M, Campone M, Soin J, Paluch-Shimon S, Huber J, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol 2017;35(32):3638–46.

Salvador EMC J, Jiménez-Rodríguez B, De La Cruz L, Villanueva Vázquez R, De Toro R, Antón A, Moreno F, Alvarez I, Quiroga V, de la Haba J, González-Santiago S, Díaz N, Barnadas A, Cantos B, Delgado Mingo ance I, Bellet Ezquerra M, Martín M, Martínez N, Vicente E. Interim results from ComPLEximent-1 (A phase 3b study of ribociclib and letrozole as first-line therapy for advanced breast cancer in an expanded population): Spanish cohort results. Ann Oncol 2019;30:v104–42.

Sonke GS, Hart LL, Campone M, Erdkamp F, Janni W, Verma S, et al. Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial. Breast Cancer Res Treat 2018;167(3):659–69.

Tesarova P. Breast cancer in the elderly-Should it be treated differently? Rep Pract Oncol Radiother 2012;18(1):26–33.

Battisti NML, De Glas N, Sedrak MS, Loh KP, Liposits G, Soto-Perez-de-Celis E, et al. Use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in older patients with ER-positive HER2-negative breast cancer: young International Society of Geriatric Oncology review paper. Ther Adv Med Oncol 2018;10:1758835918809610.